以岭药业(002603) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥1,784,116,767.07, a decrease of 25.02% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2023 was ¥152,663,394.73, down 58.26% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥99,351,589.13, a decline of 72.80% compared to the previous year[4] - The basic earnings per share for Q3 2023 was ¥0.0914, a decrease of 58.26% year-on-year[4] - Total operating revenue for Q3 2023 reached ¥8.57 billion, an increase of 7.9% compared to ¥7.95 billion in Q3 2022[16] - Operating profit for the period was ¥2.13 billion, up 21.3% from ¥1.76 billion in the same period last year[17] - Net profit attributable to shareholders was ¥1.76 billion, representing a 24.3% increase from ¥1.41 billion in Q3 2022[17] - The company reported a basic earnings per share of ¥1.0527, up from ¥0.8465 in the same quarter last year[18] Assets and Liabilities - Total assets at the end of Q3 2023 reached ¥17,435,003,796.98, an increase of 6.73% from the end of the previous year[4] - Total assets increased to ¥17,435,003,796.98 from ¥16,338,199,482.16, reflecting a growth of about 6.7%[14] - Total liabilities increased to ¥5.59 billion, compared to ¥5.41 billion in the previous year, reflecting a growth of 3.5%[17] - The total current liabilities were CNY 4,693,328,260.43, with accounts payable constituting CNY 1,353,484,539.85[28] - The company’s long-term liabilities totaled CNY 382,220,385.11, including long-term borrowings of CNY 200,150,000.00[28] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥144,622,598.35, down 88.18% compared to the same period last year[8] - The net cash received from operating activities decreased by 2.0% year-on-year, indicating a need for improved cash flow management[19] - The net cash flow from operating activities for Q3 2023 was CNY 144.62 million, a decrease of 88.2% compared to CNY 1.22 billion in Q3 2022[20] - The total cash outflow from operating activities reached CNY 7.52 billion, up 13.9% from CNY 6.60 billion in the same period last year[20] - Cash inflow from financing activities totaled CNY 1.30 billion, down from CNY 1.74 billion in Q3 2022[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 225,613[10] - The largest shareholder, Yiling Pharmaceutical Technology Co., Ltd., holds 31.53% of shares, totaling 526,775,963 shares[10] - The total equity attributable to shareholders reached ¥11.86 billion, an increase of 8.4% from ¥10.93 billion in the previous year[17] - The company reported a total equity of CNY 10.93 billion as of January 1, 2023, unchanged from the previous reporting period[24] - The total equity attributable to shareholders reached CNY 10,932,217,365.93 as of October 1, 2023[28] Investment Activities - The company’s investment activities generated a cash outflow of ¥1,111,287,071.88, an increase of 195.41% compared to the previous year[8] - Cash inflow from investment activities was CNY 3.01 billion, significantly higher than CNY 645.69 million in Q3 2022[20] - The net cash flow from investment activities was negative at CNY 1.11 billion, worsening from a negative CNY 376.18 million in the previous year[20] Other Financial Metrics - The company reported a significant increase in financial expenses, which rose by 80.26% to ¥9,453,094.72 due to higher interest costs[8] - Research and development expenses amounted to ¥593.71 million, a rise of 7.6% compared to ¥551.68 million in the previous year[17] - The company has a total of 10,610,169,718.53 in non-current assets, up from 9,084,012,200.72, indicating a growth of approximately 16.8%[14] - The company’s total non-current assets amounted to CNY 5,212,537,485.99, with long-term equity investments at CNY 1,450,308,390.41[27] Government Subsidies - The company received government subsidies amounting to ¥73,571,933.77 in Q3 2023, compared to ¥113,157,046.66 for the year-to-date[5] Audit Status - The report for the third quarter of 2023 was not audited[29]